[Current assessment of radioimmunological determination (RIA) of prostate acid phosphatase in the diagnosis of prostatic cancer].
Sera of patients without any tumors of the prostate and sera of patients with benign and malignant tumors of the prostate were tested with the enzyme assay using thymolphthalein monophosphate as substrate. The results were compared with the RIA of Clinical Assay (Travenol) and found to yield an approximately 50% better recognition of malignant growth. However, false-positive rates were rather high (approximately 20%), which lowers the overall success rate to approximately 30%.